

## Abstract 2004

---

### 1. Localization of Calcitonin Receptor mRNA in Rat Kidney: an *In Situ* Hybridization Study

Aiko Ishii<sup>1</sup>, Misa Nakamura<sup>1</sup>, Atsushi Nakamura, Masaaki Kimura and Kennichi Kakudo<sup>1</sup>

<sup>1</sup>Department of Pathology, Wakayama Medical University

Acta Histochem. Cytochem., 37(4), 259-265, 2004

### 2. Accumulation of phosphorylated $\alpha$ -synuclein in the brain and peripheral ganglia of patients with multiple system atrophy

Makoto Nishie<sup>1</sup>, Fumiaki Mori<sup>1</sup>, Hideo Fujiwara<sup>2</sup>, Masato Hasegawa<sup>3</sup>, Makoto Yoshimoto, Takeshi Iwatsubo<sup>2</sup>, Hitoshi Takahashi<sup>4</sup>, Koichi Wakabayashi<sup>1</sup>

<sup>1</sup>Department of Neuropathology, Institute of Brain Science, Hirosaki University School of Medicine

<sup>2</sup>Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Science, The University of Tokyo

<sup>3</sup>Department of Molecular Neurobiology, Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research

<sup>4</sup>Department of Pathology, Brain Research Institute, Niigata University

Acta Neuropathol., 107, 292-298, 2004

### 3. Scratching behavior in NC/Nga mice with dermatitis: Involvement of histamine-induced itching

Yuki Hashimoto, Norikazu Takano, Atsushi Nakamura, Shiro Nakaike, Zhigian Yu<sup>1</sup>, Yasuo Endo<sup>1</sup> and Iwao Arai

<sup>1</sup>Department of Molecular Regulation, Graduate School of Dentistry, Tohoku University

Allergology International, 53, 349-358, 2004

**4. VGA1155, a Novel Binding Antagonist of VEGF, Inhibits Angiogenesis *In Vitro* and *In Vivo***

YASUJI UEDA, TAKEHIRO YAMAGISHI, HISAO IKEYA, NORIKO HIRAYAMA, TAKASHI ITOKAWA<sup>1</sup>, YASUSHI AOZUKA<sup>2</sup>, KAZUNORI SAMATA, SHIRO NAKAIKE, MAKOTO TANAKA, MAYUMI ONO and IKUOSAIKI<sup>2</sup>

<sup>1</sup>Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University

<sup>2</sup>Department of Pathogenic Biochemistry, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University

Anticancer Research, 24, 3009-3018, 2004

**5. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group I metabotropic glutamate receptor antagonist, MGS0039**

Takao Yoshimizu and Shigeyuki Chaki

Biochemical and Biophysical Research Communications, 315, 493-496, 2004

**6. Involvement of caspase-9 in execution of the maternal program of apoptosis in *Xenopus* late blastulae overexpressed with S-adenosylmethionine decarboxylase**

Eiji Takayama<sup>1</sup>, Takayasu Higo<sup>2</sup>, Masatake Kai<sup>2</sup>, Masashi Fukasawa<sup>3</sup>, Keisuke

Nakajima<sup>4</sup>, Hiroshi Hara, Takushi Tadakuma<sup>1</sup>, Kazuei Igarashi<sup>5</sup>, Yoshio Yaoita<sup>4</sup>, Koichiro Shiokawa<sup>2</sup>

<sup>1</sup>Department of Parasitology and Immunology, National Defense Medical College

<sup>2</sup>Laboratory of Molecular Embryology, Department of Biological Science, Graduate School of Sciences, The University of Tokyo

<sup>3</sup>Department of Microbiology, National, Defense Medical College

<sup>4</sup>Department of Molecular Neurobiology, Tokyo Metropolitan Institute for Neuroscience

<sup>5</sup>Graduate School of Pharmaceutical Sciences, Chiba University

Biochemical and Biophysical Research Communications, 325, 1367-1375, 2004

**7. Sweet Potato Acid Phosphatase Immobilized on Glutaraldehyde-Activated Aminopropyl Controlled-Pore Glass: Activation, Repeated Use and Enzyme Fatigue**

Susumu YAMATO<sup>1</sup>, Nozomi KAWAKAMI<sup>1</sup>, Kenji SHIMADA<sup>1</sup>, Masaki ONO, Naoko IDEI, Yuji ITOH, and Eiichi TACHIKAWA<sup>2</sup>

<sup>1</sup>Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences

<sup>2</sup>Department of Pharmacology, School of Medicine, Iwate Medical University

Biol. Pharm. Bull., 27(2), 210-215, 2004

**8. Design, synthesis and structure-affinity relationships of aryloxyanilide derivatives as novel peripheral benzodiazepine receptor ligands**

Taketoshi Okubo, Ryoko Yoshikawa, Shigeyuki Chaki, Shigeru Okuyama and Atsuro Nakazato

Bioorganic & Medicinal Chemistry, 12, 423-438, 2004

**9. Design, synthesis, and structure-activity relationships of novel tetracyclic compounds as peripheral benzodiazepine receptor ligands**

Taketoshi Okubo, Ryoko Yoshikawa, Shigeyuki Chaki, Shigeru Okuyama and Atsuro Nakazato

Bioorganic & Medicinal Chemistry, 12, 3569-3580, 2004

**10. Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase inhibitors**

Hiroshi Fukushima, Akira Hiratate, Masato Takahashi, Masako Saito, Eiji Munetomo, Kiyokazu Kitano, Hidetaka Saito, Yuji Takaoka and Koji Yamamoto

Bioorganic & Medicinal Chemistry, 12, 6053-6061, 2004

**11. Pyrazole derivatives as new potent and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors**

Toshio Nakamura, Hiroyuki Kakinuma, Hideaki Amada, Noriyuki Miyata, Kazuo Taniguchi, Ayumi Koda and Masakazu Sato

Bioorganic & Medicinal Chemistry, 12, 6209-6219, 2004

**12. Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors**

Toshio Nakamura, Hiroyuki Kakinuma, Hiroki Umemiya, Hideaki Amada, Noriyuki Miyata, Kazuo Taniguchi, Kagumi Bando and Masakazu Sato

Bioorganic & Medicinal Chemistry Letters, 14, 333-336, 2004

**13. Design and synthesis of 1-(4-benzoylphenyl)imidazole derivatives as new potent 20-HETE synthase inhibitors**

Toshio Nakamura, Takaaki Ishii, Noriyuki Miyata, Kazuo Taniguchi, Yasumitsu Tomishima, Tomokazu Ueki and Masakazu Sato

Bioorganic & Medicinal Chemistry Letters, 14, 5305-5308, 2004

**14. The Role of the DRY Motif of Human MC4R for Receptor Activation**

Yoshiaki YAMANO<sup>1</sup>, Rio KAMON<sup>1</sup>, Takao YOSHIMIZU, Yoshihisa TODA, Yuichi OSHIDA, Shigeyuki CHAKI, Masanobu YOSHIOKA<sup>1</sup>, and Isao MORISHIMA<sup>1</sup>

<sup>1</sup>Department of Biochemistry and Biotechnology, Faculty of Agriculture, Tottori University

Biosci. Biotechnol. Biochem., 68(6), 1369-1371, 2004

**15. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth**

Yasuji Ueda, Takehiro Yamagishi, Kazunori Samata, Hisao Ikeya, Noriko Hirayama, Tadayasu Okazaki, Sumi Nishihara, Koshi Arai, Sachiko Yamaguchi<sup>1</sup>, Masabumi Shibuya<sup>1</sup>, Shiro Nakaike, Makoto Tanaka

<sup>1</sup>Department of Genetics, Institute of Medical Science, University of Tokyo

Cancer Chemother Pharmacol, 54, 16-24, 2004

**16. CATALYTIC ROLES OF CYP2C9 AND ITS VARIANTS (CYP2C9\*2 AND CYP2C9\*3) IN LORNOXICAM 5'-HYDROXYLATION**

IZUMI IIDA, ATSUNORI MIYATA, MASAYUKI ARAI, MITSUYO HIROTA,  
MASAYUKI AKIMOTO, SHOHEI HIGUCHI, KAORU KOMAYASHI<sup>1</sup>, KAN  
CHIBA<sup>1</sup>

<sup>1</sup>Graduate School of Pharmaceutical Sciences, Chiba University

Drug Metabolism and Disposition, 32(1), 7-9, 2004

### **17. Direct Nose-to-Brain Delivery 医薬の開発は可能か？**

山田憲司

Drug Metabolism and Pharmacokinetics, 19(4), 4-5, 2004

### **18. Functional Characterization of Single Nucleotide Polymorphisms with Amino Acid Substitution in CYP1A2, CYP2A6, and CYP2B6 Found in the Japanese Population**

Masahiko IWASAKI<sup>1</sup>, Yoshinobu YOSHIMURA<sup>2</sup>, Satoru ASAHI<sup>3</sup>, Kimitoshi SAITO<sup>4</sup>, Shuichi SAKAI<sup>4</sup>, Shigemichi MORITA<sup>5</sup>, Osamu TAKENAKA<sup>6</sup>, Toshio INODA<sup>7</sup>, Eiji KASHIYAMA<sup>8</sup>, Akinori AOYAMA<sup>9</sup>, Takeshi NAKABAYASHI<sup>10</sup>, Satoshi OMORI<sup>11</sup>, Takashi KUWABARA<sup>12</sup>, Takashi IZUMI<sup>13</sup>, Kouichi NAKAMURA<sup>13</sup>, Kaoru TAKANAKA<sup>13</sup>, Yukiharu NAKAYAMA<sup>14</sup>, Mitsuaki TAKEUCHI<sup>14</sup>, Hideki NAKAMURA<sup>15</sup>, Shunichi KAMETANI, Yoshiaki TERAUCHI<sup>16</sup>, Takanori HASHIZUME<sup>16</sup>, Sekio NAGAYAMA<sup>17</sup>, Toshiyuki KUME<sup>18</sup>, Meguru ACHIRA<sup>18</sup>, Hiroyuki KAWAI<sup>19</sup>, Takashi KAWASHIRO<sup>20</sup>, Akio NAKAMURA<sup>21</sup>, Yasuhiro NAKAI<sup>22</sup>, Akira KAGAYAMA<sup>23</sup>, Toshifumi SHIRAGA<sup>23</sup>, Takuro NIWA<sup>24</sup>, Takuya YOSHIMURA<sup>24</sup>, Jun MORITA<sup>25</sup>, Fukuichi OHSAWA<sup>25</sup>, Masato TANI<sup>25</sup>, Nobuo OSAWA<sup>26</sup>, Keiichi IDA<sup>26</sup> and Kiyoshi NOGUCHI<sup>27</sup>

<sup>1</sup>Graduate School of Osaka University

<sup>2</sup>Takeda Analytical Research Laboratories, Ltd.

<sup>3</sup>Takeda Chemical Industries, Ltd.

<sup>4</sup>Chugai Pharmaceutical Co., Ltd.

- <sup>5</sup>Aventis Pharma Ltd.  
<sup>6</sup>Eisai Co., Ltd.  
<sup>7</sup>SS Pharmaceutical Co., Ltd.  
<sup>8</sup>Otsuka Pharmaceutical Co., Ltd.  
<sup>9</sup>Kaken Pharmaceutical Co., Ltd.  
<sup>10</sup>Kissei Pharmaceutical Co., Ltd.  
<sup>11</sup>Kyorin Pharmaceutical Co., Ltd.  
<sup>12</sup>Kyowa Hakko Kogyo Co., Ltd.  
<sup>13</sup>Sankyo Co., Ltd.  
<sup>14</sup>Sanwa Kagaku Kenkyusho Co., Ltd.  
<sup>15</sup>Zeria Pharmaceutical Co., Ltd.  
<sup>16</sup>Dainippon Pharmaceutical Co., Ltd.  
<sup>17</sup>Taiho Pharmaceutical Co., Ltd.  
<sup>18</sup>Tanabe Seiyaku Co., Ltd.  
<sup>19</sup>Nikken Chemicals Co., Ltd.  
<sup>20</sup>Nippon Kayaku Co., Ltd.  
<sup>21</sup>Nippon Shinyaku Co., Ltd.  
<sup>22</sup>Pfizer Japan Inc.  
<sup>23</sup>Fujisawa Pharmaceutical Co., Ltd.  
<sup>24</sup>Mitsubishi Pharma Corporation  
<sup>25</sup>Meiji Seika Kaisha Ltd.  
<sup>26</sup>Mochida Pharmaceutical Co., Ltd.  
<sup>27</sup>Yamanouchi Pharmaceutical Co., Ltd.

Drug Metab. Pharmacokinet., 19(6), 444-452, 2004

## **19. The MC4 receptor as a therapeutic target**

Shigeyuki Chaki and Atsuro Nakazato

Drugs of the Future, 29(10), 1065-1074, 2004

## **20. The in vitro metabolism of desglymidodrine, an active metabolite of prodrug midodrine by human liver microsomes**

MASAYUKI AKIMOTO<sup>1</sup>, IZUMI IIDA, HIROKI ITOGA, ATSUNORI MIYATA,  
SHIZUKO KAWAHARA, and YOSHIRO KOHNO

<sup>1</sup>Faculty of Pharmaceutical Sciences, Josai International University

European Journal of Drug Metabolism and Pharmacokinetics, 29(3), 179-186, 2004

**21. Anxiolytic- and antidepressant-like profile of a new CRF<sub>1</sub> receptor antagonist, R278995/CRA0450**

Shigeyuki Chaki, Atsuro Nakazato, Ludo Kennis<sup>1</sup>, Masato Nakamura, Claire Mackie<sup>1</sup>, Masayuki Sugiura, Petra Vinken<sup>1</sup>, David Ashton<sup>1</sup>, Xavier Langlois<sup>1</sup>, Thomas Steckler<sup>1</sup>

<sup>1</sup>Johnson & Johnson Pharmaceutical Research and Development, Division of Pharmaceutica N.V.

European Journal of Pharmacology, 485, 145-158, 2004

**22. Evaluation of antipruritic effects of several agents on scratching behavior by NC/Nga mice**

Norikazu Takano, Iwao Arai, Yuki Hashimoto, Michio Kurachi

European Journal of Pharmacology, 495, 159-165, 2004

**23. Anxiolytic-like activity of MGS0039, a potent group 1 metabotropic glutamate receptor antagonist, in a marble-burying behavior test**

Toshiharu Shimazaki, Michihiko Iijima, Shigeyuki Chaki

European Journal of Pharmacology, 501, 121-125, 2004

**24. Effects of SEA0400, a novel inhibitor of the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger, on myocardial stunning in anesthetized dogs**

Teisuke Takahashi, Kenzo Takahashi, Michihito Onishi, Taizo Suzuki, Yu Tanaka, Tomomi Ota, Shigeru Yoshida, Shiro Nakaike, Toshio Matsuda<sup>1</sup>, Akemichi Baba<sup>2</sup>

<sup>1</sup>Laboratory of Medical Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University

<sup>2</sup>Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University

European Journal of Pharmacology, 505, 163-168, 2004

**25. Prostanoid DP<sub>1</sub> receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis**

Iwao Arai, Norikazu Takano, Yuki Hashimoto, Nobuko Futaki, Masanori Sugimoto, Nobutaka Takahashi, Tomoyuki Inoue, Shiro Nakaike

European Journal of Pharmacology, 505, 229-235, 2004

**26. マクロライド抗生物質開発研究の最前線**

Toshifumi ASAKA, Hajime TAKASHIMA

Farumashia, 40(6), 517-521, 2004

**27. がんアポトーシスを選択的に誘導する低分子化合物**

Hiroyuki KAKINUMA

Farumashia, 40(7), 672-673, 2004

**28. Ursolic acid, an antagonist for transforming growth factor (TGF)- 1**

Shigeru Murakami, Hajime Takashima, Mariko Sato-Watanabe, Sumi Chonan, Koji Yamamoto, Masako Saitoh, Shiuji Saito, Hiromitsu Yoshimura, Koko Sugawara, Junshan Yang<sup>1</sup>, Nannan Gao<sup>1</sup>, Xinggao Zhang<sup>1</sup>

<sup>1</sup>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical Collage

FEBS Letters, 566, 55-59, 2004

**29. Transforming growth factor- induced stimulation of formation of collagen fiber network and anti-fibrotic effect of taurine in an in vitro model of hepatic fibrosis**

Junya Kato<sup>1</sup>, Akio Ido<sup>1,2</sup>, Satoru Hasuike<sup>1</sup>, Hirofumi Uto<sup>1</sup>, Takeshi Hori<sup>1</sup>, Katsuhiko Hayashi<sup>1</sup>, Shigeru Murakami, Akira Terano<sup>3</sup>, Hirohito Tsubouchi<sup>1,2</sup>

<sup>1</sup>Department of Internal Medicine , Faculty of Medicine, University of Miyazaki

<sup>2</sup>Department of Experimental Therapeutics, Translational Research Center, Kyoto University Hospital

<sup>3</sup>Department of Gastroenterology, Dokkyo University School of Medicine

Hepatology Research, 30, 34-41, 2004

**30. CONFORMATIONAL ANALYSIS OF TRICYCLIC KETOLIDE TE-802 AND ITS ANALOGUES**

Masato Kashimura, Keita Matsumoto, Toshifumi Asaka, and Shigeo Morimoto

Heterocycles, 63(9), 2057-2070, 2004

**31. STAT6-mediated signaling in Th2-dependent allergic asthma: critical role for the development of eosinophilia, airway hyper-responsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation**

Akihiko Hoshino, Takemasa Tsuji<sup>1</sup>, Junko Matsuzaki<sup>1</sup>, Takafumi Jinushi<sup>1</sup>, Shigeru Ashino<sup>1</sup>, Takashi Teramura<sup>1</sup>, Kenji Chamoto<sup>1</sup>, Yoshitaka Tanaka, Yumiko Asakura, Takanobu Sakurai, Yasuo Mita, Akiko Takaoka, Shiro Nakaike, Tsuguhide Takeshima<sup>1</sup>, Hiroaki Ikeda<sup>1</sup> and Takeshi Nishimura<sup>1</sup>

<sup>1</sup>Division of Immunoregulation, Institute for Genetic Medicine, Hokkaido University

International Immunology, 16(10), 1497-1505, 2004

**32. セルフメディケーションと OTC**

浜野正一郎

Japanese Journal of Drug Informatics, 5(4), 171-174, 2004

**33. Structure Revision of FD-891, a 16-Membered Macrolide Antibiotic**

TADASHI EGUCHI<sup>1</sup>, KEITA YAMAMOTO<sup>1</sup>, KAZUTOSHI MIZOUE and KATSUMI KAKINUMA<sup>2</sup>

<sup>1</sup>Department of Chemistry and Materials Science, Tokyo Institute of Technology

<sup>2</sup>Department of Chemistry, Tokyo Institute of Technology

Journal of Antibiotics, 57(2), 156-157, 2004

**34. *In Vitro* and *In Vivo* Antibacterial Activities of the Tricyclic Ketolide**

## **TE-802 and Its Analogs**

TAKEO ONO, MASATO KASHIMURA, KEIKO SUZUKI, RIKA OYAUCHI,  
JUNKO MIYACHI, HIROSHI IKUTA, HIROYUKI KAWAUCHI, TOSHI AKASHI,  
TOSHIFUMI ASAKA and SHIGEO MORIMOTO

*Journal of Antibiotics*, 57(8), 518-527, 2004

### **35. Development of a novel analytical method for determination of chondroitin sulfate using an in-capillary enzyme reaction**

Hitoshi Okamoto, Toshiaki Nakajima, Yuji Ito, Kenji Shimada<sup>1</sup>, Susumu Yamato<sup>1</sup>

<sup>1</sup>Department of Analytical Chemistry, Niigata University of Pharmacy and Applied Life Science

*Journal of Chromatography A*, 1035, 137-144, 2004

### **36. Therapeutic potential of an anti-inflammatory receptor, EP4, in macrophage activation**

Kiyoshi TAKAYAMA

*Journal of Clinical and Experimental Medicine (IGAKU NO AYUMI)*, 209(8), 465-469, 2004

### **37. Possible antipruritic effects of K<sup>+</sup> channel openers in mice**

Norikazu Takano, Iwao Arai, Michio Kurachi

*Journal of Dermatological Science*, 35, 71-73, 2004

**38. Persistence of *Staphylococcus aureus* colonization on the skin of NC/Nga mice**

Yuki Hashimoto, Yoshie Kaneda, Toshi Akashi, Iwao Arai, Shiro Nakaike

Journal of Dermatological Science, 35, 143-150, 2004

**39. Synthesis, in Vitro Pharmacology, Structure-Activity Relationships, and Pharmacokinetics of 3-Alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Derivatives as Potent and Selective Group Metabotropic Glutamate Receptor Antagonists**

Atsuro Nakazato, Kazunari Sakagami, Akito Yasuhara, Hiroshi Ohta, Ryoko Yoshikawa, Manabu Itoh, Masato Nakamura, and Shigeyuki Chaki

Journal of Medicinal Chemistry, 47(18), 4570-4587, 2004

**40. 製剤が評価可能な薬物吸収予測システム**

Takafumi Ohashi

Journal of Pharmaceutical Science and Technology, Japan (YAKUZAIGAKU), 64(1), 44-49, 2004

**41. Inhibitory Profile of SEA0400 [2-[4-[(2,5-Difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline] Assessed on the Cardiac Na<sup>+</sup>-Ca<sup>2+</sup> Exchanger, NCX1.1**

Candace Lee<sup>1</sup>, Neeraj S. Visen<sup>1</sup>, Naranjan S. Dhalla<sup>1</sup>, Hoa Dinh Le<sup>1</sup>, Michael Isaac<sup>1</sup>, Platon Choptiany<sup>1</sup>, Gil Gross<sup>2</sup>, Alexander Omelchenko<sup>1</sup>, Toshio Matsuda<sup>3</sup>, Akemichi Baba<sup>3</sup>, Kenzo Takahashi, Mark Hnatowich<sup>1</sup>, and Larry V. Hryshko<sup>1</sup>

<sup>1</sup>Institute of Cardiovascular Sciences, St. Boniface Hospital Research Centre

<sup>2</sup>Division of Cardiology, Hospital for Sick Children

<sup>3</sup>Graduate School of Pharmaceutical Sciences, Osaka University

Journal of Pharmacology and Experimental Therapeutics, 311(2), 748-757, 2004

#### **42. Regulation of CRF, POMC and MC4R Gene Expression after Electrical Foot Shock Stress in the Rat Amygdala and Hypothalamus**

Yoshiaki YAMANO<sup>1</sup>, Masanobu YOSHIOKA<sup>1</sup>, Yoshihisa TODA, Yuichi OSHIDA, Shigeyuki CHAKI, Kaori HAMAMOTO<sup>1</sup> and Isao MORISHIMA<sup>1</sup>

<sup>1</sup>Department of Biochemistry and Biotechnology, Faculty of Agriculture, Tottori University

J. Vet. Med. Sci., 66(11), 1323-1327, 2004

#### **43. Development of *Iris CL-1* Contact Lenses**

T. Ohtsuki

JPI Journal, 42(5), 425-430, 2004

#### **44. Monkey corticotrophin-releasing factor<sub>1</sub> receptor: Complementary DNA cloning and pharmacological characterization**

Yuichi Oshida, Yoko Ikeda, Shigeyuki Chaki, Shigeru Okuyama

Life Sciences, 74, 1911-1924, 2004

#### **45. Scratching of their skin by NC/Nga mice leads to development of dermatitis**

Yuki Hashimoto, Iwao Arai, Yutaka Nakanishi, Takanobu Sakurai, Atsushi Nakamura, Shiro Nakaike

Life Sciences, 76, 783-794, 2004

**46. Compounding change of the prostaglandin E1 preparation (lipo PGE1) for intravenous infusion on sale**

Yasuo Watanabe, Noriko Takahashi, Tetsuo Yamaguchi, Minoru Koji, Shusei Ito, Masao Huruichi<sup>1</sup>

<sup>1</sup>株式会社 住化分析センター ファーマ事業部

Medicine and Drug Journal, 40(5), 1489-1494, 2004

**47. Effects of SEA0400 on Mutant NCX1.1 Na<sup>+</sup>-Ca<sup>2+</sup> Exchangers with Altered Ionic Regulation**

Ron Bouchard<sup>1</sup>, Alexander Omelchenko<sup>1</sup>, Hoa Dinh Le<sup>1</sup>, Platon Choptiany<sup>1</sup>, Toshio Matsuda<sup>2</sup>, Akemichi Baba<sup>2</sup>, Kenzo Takahashi, Debora A. Nicoll<sup>3</sup>, Kenneth D. Philipson<sup>3</sup>, Mark Hnatowich<sup>1</sup>, and Larry V. Hryshko<sup>1</sup>

<sup>1</sup>Institute of Cardiovascular Sciences, University of Manitoba, Faculty of Medicine, St. Boniface Research Centre

<sup>2</sup>Graduate School of Pharmaceutical Sciences, Osaka University

<sup>3</sup>UCLA Cardiovascular Research Labs

Molecular Pharmacology, 65(3), 802-810, 2004

**48. Mutations induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in the *lacZ* and *c* genes of Muta<sup>TM</sup>Mouse**

Kiyohiro Hashimoto, Koh-ichi Ohsawa, Masaaki Kimura

Mutation Research, 560, 119-131, 2004

**49. Studies on Rehmanniae Radix. V. 5-Hydroxymethyl-2-furaldehyde, Active Constituent of the Steamed Root of Rehmannia glutinosa Having Increasing Activity of Erythrocyte Deformability in Rats**

Hideaki Matsuda<sup>1</sup>, Yasuyuki Tsukioka<sup>2</sup>, Kenzo Moriyama<sup>3</sup>, Takahiro Shintani<sup>3</sup>, Toshiki Asano, Hidemi Shiimoto and Michinori Kubo<sup>1,3</sup>

<sup>1</sup>School of Pharmaceutical Sciences, Kinki University

<sup>2</sup>Department of Pharmacy, Kinki University Hospital

<sup>3</sup>The Institute of Oriental Medicine, Kinki University

Natural Medicines, 58(1), 34-37, 2004

**50. Salt-sensitive hypertension is triggered by Ca<sup>2+</sup> entry via Na<sup>+</sup>/Ca<sup>2+</sup> exchanger type-1 in vascular smooth muscle**

Takahiro Iwamoto<sup>1,3</sup>, Satomi Kita<sup>1</sup>, Jin Zhang<sup>2</sup>, Mordecai P Blaustein<sup>2</sup>, Yuji Arai<sup>4</sup>, Shigeru Yoshida, Koji Wakimoto<sup>5</sup>, Issei Komuro<sup>6</sup> & Takeshi Katsuragi<sup>1</sup>

<sup>1</sup>Department of Pharmacology, School of Medicine, Fukuoka University

<sup>2</sup>Department of Physiology, University of Maryland School of Medicine

Department of <sup>3</sup>Molecular Physiology and <sup>4</sup>Bioscience, National Cardiovascular Center Research Institute

<sup>5</sup>Discovery Research Laboratory, Tanabe Seiyaku Co.,Ltd.

<sup>6</sup>Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine

Nature Medicine, 10(11), 1193-1199, 2004

**51. A quantitative investigation of neuronal cytoplasmic and intranuclear**

**inclusions in the pontine and inferior olivary nuclei in multiple system atrophy**

M. Nishie<sup>1</sup>, F. Mori<sup>1</sup>, M. Yoshimoto, H. Takahashi<sup>2</sup> and K. Wakabayashi<sup>1</sup>

<sup>1</sup>Department of Neuropathology, Institute of Brain Science, Hirosaki University School of Medicine

<sup>2</sup>Department of Pathology, Brain Research Institute, Niigata University

Neuropathology and Applied Neurobiology, 30, 546-554, 2004

**52. MGS0039: a potent and selective group metabotropic glutamate receptor antagonist with antidepressant-like activity**

Shigeyuki Chaki, Ryoko Yoshikawa, Shiho Hirota, Toshiharu Shimazaki, Naoko Maeda, Naoya Kawashima, Takao Yoshimizu, Akito Yasuhara, Kazunari Sakagami, Shigeru Okuyama, Shigetada Nakanishi<sup>1</sup>, Atsuro Nakazato

<sup>1</sup>Department of Biological Sciences, Kyoto University Faculty of Medicine

Neuropharmacology, 46, 457-467, 2004

**53. P-VECP can reveal visual toxicity in pigmented rats of repeated doses of ethambutol**

Shoji Sasaki, Kumiko Yagi, Hiroto Miyata, Isamu Nakamura, Yoshinobu Iwaki, Masaaki Kimura

Neurotoxicology and Teratology, 26, 279-284, 2004

**54. PQRI におけるリスクと品質の定義およびリスクマネジメントの現状と展望**

横森貞和

PDA Journal of GMP and Validation in Japan, 6(2), 76-80, 2004

**55. High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method**

T. YAMAMOTO, A. SUZUKI and Y. KOHNO

Xenobiotica, 34(1), 87-101, 2004

**56. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vivo metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs**

T. YAMAMOTO, N. HAGIMA, M. NAKAMURA, Y. KOHNO, K. NAGATA<sup>1</sup> and Y. YAMAZOE<sup>1</sup>

<sup>1</sup>Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University

Xenobiotica, 34(7), 687-703, 2004

**57.**